Wall Street is positive on PhaseBio Pharmaceuticals Inc (PHAS). On average, analysts give PHAS a Strong Buy rating. The average price target is $13.333, which means analysts expect the stock to add by 287.59% over the next twelve months.
That average ranking earns PHAS an Analyst Rating of 80, which is better than 80% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
Investors Observer averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With PhaseBio Pharmaceuticals Inc Stock Today?
PhaseBio Pharmaceuticals Inc (PHAS) stock has risen 6.74% while the S&P 500 has fallen -0.11% as of 2:16 PM on Thursday, Sep 10. PHAS has gained $0.22 from the previous closing price of $3.22 on volume of 154,484 shares. Over the past year the S&P 500 has gained 13.14% while PHAS has fallen -38.68%. PHAS lost -$2.29 per share the over the last 12 months.
Click Here to get the full report on PhaseBio Pharmaceuticals Inc (PHAS) Stock.